Dana Investment Advisors Inc. Decreases Holdings in Bristol Myers Squibb Company $BMY

Dana Investment Advisors Inc. cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 46.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 48,278 shares of the biopharmaceutical company’s stock after selling 42,334 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Bristol Myers Squibb were worth $2,604,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in BMY. Brighton Jones LLC raised its stake in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 2,786 shares during the period. United Bank increased its stake in shares of Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,277 shares during the period. Marshall Wace LLP purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $221,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $405,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on BMY shares. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. UBS Group reaffirmed a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective on the stock. Finally, Piper Sandler reissued an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Stock Up 0.1%

Shares of Bristol Myers Squibb stock opened at $57.04 on Monday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company’s fifty day simple moving average is $58.63 and its two-hundred day simple moving average is $55.43. The company has a market cap of $116.48 billion, a P/E ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.26. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the previous year, the business posted $1.80 EPS. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.31 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb’s $15.2 billion collaboration and licensing deal with Hengrui Pharma expands its pipeline with 13 early-stage programs, a major long-term growth catalyst. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: Zacks Research raised earnings estimates for FY2026, FY2027, FY2028 and several quarterly periods, suggesting improved profitability expectations for BMY. MarketBeat Bristol Myers Squibb estimates update
• Positive Sentiment: Tempus expanded its strategic collaboration with Bristol Myers Squibb to use AI and real-world data to improve clinical development success in oncology and neuroscience. Tempus expands strategic collaboration with Bristol Myers Squibb
• Positive Sentiment: Tigerlily Foundation announced a collaboration with Bristol Myers Squibb to expand clinical trial access and reduce participation barriers, supporting the company’s ESG and patient-access profile. Tigerlily Foundation collaborates with Bristol Myers Squibb
• Neutral Sentiment: Bristol Myers Squibb presented at the Bank of America Global Healthcare Conference, which is typically informational rather than a direct stock-moving event. Bristol-Myers Squibb Company presents at conference transcript
• Neutral Sentiment: Analyst commentary on BMY’s valuation and “buy, sell, or hold” status adds context, but it does not appear to be a new fundamental catalyst. Bristol-Myers Squibb buy sell or hold post Q1 earnings
• Negative Sentiment: One article highlighted a recent pullback in BMY shares, reminding investors that momentum has been uneven despite the recent rally. Bristol-Myers Squibb Stock Falls 3.9% After May 2026 Pullback

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.